Pr

1
Inserm French National Institute of Health
and Medical Research

• Created in 1964 from the National Institute of
  Hygiene and Hospital Research

• Working through the
• Ministries for Research and Health

2
Inserm key figures
335 Inserm laboratories 19 research centers
41 Clinical Investigation Centers (CIC)
Budget 2007 700 M Total staff 13 000 (2 500
physicians) of which 4900 Inserm employees 2100
scientists and 2800 technical staff (62 of
total budget dedicated to salaries)
374 French and foreign firms are partners of
Inserm
An active patent portfolio of 572 families
56 start-up companies based on Inserm technology
3
What is Inserm ?

• The French performing research organisation
  entirely dedicated to Biomedical Clinical
  research and Public Health
• All fields of research are covered in these
  domains
• 90 of the 365 research units are located in
  University hospitals
• Research units with 8 years mandate with mid-term
  (4 year) evaluation. Stringent evaluation
• Investigator- driven projects - AVENIR programme
• Close collaboration with French Funding agencies
  (ANR, INCa ANRS), Sanitary agencies (InVS,
  AFSSAPS), Charities (AFM, ) and industrial
  partners.

4
The Inserm performance
aboutblank
5
Organization

• Bottom-up initiatives selection based on quality
  and innovation
• Networks focused on major public health issues
  National Research Programs
• Diabetes, Cardiovascular, Hepato-Gastro-
  Enterology
• Bone and joint diseases, endocrinolgy and
  reproduction etc.

6
(No Transcript)
7
(No Transcript)
8
Inserm creation of research centers

• Objectives and main characteristics
• Critical mass (100 to 300 staffs),
• Mutualisation and Integration
• International visibility, Attractiveness
• Assessment criteria
• Scientific excellence
• Quality of the management
• Governing structure, mutualised administration
  management
• Technology transfert and research outcomes
• Sharing of technical facitilies
• Coordination of scientific events and programmes
• Implementation of research training programmes
• International scientific council for evaluation
  of scientific strategy (turn-over of scientific
  teams mobility, hosting new scientists or
  teams,)

9
19 Research Centers in 2007
Some exemples 1- Paris 6, Pluri-thematic 2-
Paris 6, Neurophysiology 4- Paris 5,
Pluri-thematic 5- Créteil, Pluri-thematic 6-
Lilles, Pluri-thematic 7- Dijon,
Cancer/Nutrition 8- Bordeaux, Neurophysiology 9-
Grenoble, Neurophysiology 10- Grenoble,
Cancer 11- Toulouse, Pluri-thematic
10
Physiopathologie et thérapie des déficits
sensoriels et moteurs
Director Christian Hamel

• Partners
• Montpellier 1 et 2 Universities
• Montpellier University Hospital
• Inserm

• Thematics
• Pathophysiological studies and therapeutic
• innovation in neurosciences
• Sensory diseases auditio, vision,
  propriception
• nociception

• Facilities
• Histology
• Cellular imaging
• Human neurogenetics
• Experimental pharmacology
• Cellular and animal models

• Technology transfer
• Public-private Partnerships
• patents

Inserm Unit 583 5 teams 108 staffs Montpellier
www.inmfrance.com
11
Institut François Magendie Director Pier Vi
Piazza

• Partners
• Bordeaux 1 University
• Bordeaux University Hospital
• Inserm

Inserm Unit 862 8 teams 100 staffs Bordeaux 3
Avenir program

• Thematics
• Addictiopn physiopathology
• Neurogenesis and physiopathology
• Physiology of the neuro-endocrinal systems
• Synaptic plasticity and medullar neuronal
  netkwork
• physiopathology

• Facilities
• Small animals
• Non human primate
• Motricity
• IRM
• Biochemestry

• Technology transfer
• Public-private Partnerships

12
Département de Recherche en Cancérologie DReC Dire
ctor Marc Bonneville
Inserm Unit 601 7 teams 145 staffs Nantes

• Partners
• - Inserm
• Nantes University Hospital
• Nantes University

• Thematics
• Lymphocyte and dendritic cells
• Cytokines and receptors
• Conventional and non-conventional immunity,
• Oncology, virology
• Apoptosis and tumor progression
• Radiopharmaceutics

• Facilities
• Quantitative PCR
• Cellular imaging
• Recombinant proteins
• Histology, morphology

• Technology transfer
• 14 patents
• Public-private Partnerships

www.u601.nantes.inserm.fr
13
Institut de Médecine Moléculaire de
Rangueil I2MR
Director Angelo Parini
Inserm Unit 858 15 teams 156 staffs Toulouse

• Thematics
• Obesity, heart and kidney pathologies
• Vascular biology, inflammation and diabetes
• Epithelial cancers, angiogenesis and signalling

• Facilities
• Biotherapy
• Proteomics
• Histo-morphology
• Genomics and molecular biology
• Fonctional exploration
• Zootechnics

• Partners
• - Inserm
• Toulouse University Hospital
• Paul Sabatier University in
• Toulouse

• Technology transfer
• Public-private Partnerships

14
Centre de recherche Cardiovasculaire
Inserm CRCIL Director Bernard Lévy
Inserm Unit 689 5 teams 114 staffs Paris

• Partners
• Inserm
• Paris University Hospital
• Paris 7 University

• Thematic
• Cardiovascular
• Angiogenesis

• Facilities
• Animals
• Cell Culture
• Cytometry
• Small animal fonctional
• exploration

• Technology transfer
• 6 patents
• Public-private Partnerships

15

Director Marc Laburthe
Inserm Unit 733 11 teams 160 staffs Paris

• Partners
• Inserm
• Paris University Hospital
• Paris 7 University

• Thematics
• Gastroenterology
• Inflammation
• Receptors

• Facilities
• Quantitative PCR
• Cellular imaging
• Small animal Fonctional
• explorations
• Histology, morphology

• Technology transfer
• 3 patents
• Public-private Partnerships

16
Director Joël Bockaert

• Partners
• Inserm
• Montpellier 1 et 2 Universities
• Montpellier University Hospital
• CNRS

• Thematics
• Cancer
• Cardiovascular
• Genetic and cellular therapies
• Metabolism, endocrinology, nutrition
• Human health
• Brain

Inserm Unit 661 5 departments 159 staffs
Montpellier 1 Avenir program

• Facilities
• Transcriptomics
• Proteomics
• Photonic Imaging
• Pharmacology

• Technology transfer
• 5 patents
• Public-private Partnerships
• Sanofi
• Pfizer
• .

www.igf.cnrs.fr
17
Director D.Moras

• Partners
• - Inserm
• Louis Pasteur University
• CNRS

Inserm Unit 596 7 departments 550 staffs
Strasbourg 3 Avenir programs

• Thematics
• Molecular pathology
• Developmental and physiological gentics
• Fonctional genomics
• Cellular biologie and signal transduction
• Molecular neurobiology

• Facilities
• Cellular imaging
• DNA microarray platform
• Monoclonal Antibody
• Structural biology
• Bio-informatic
• Protéomics

• Technology transfer
• gt 20 contrats with industries
• Public-private Partnerships

www-igbmc.u-strasbg.fr
18
Research infrastructures

• National Genomic Research Consortium CNRG
• National Sequencing Center
• National Genotyping Center
• Regional Genopoles Core Facilities
• Biosafety-level 4 laboratory
• Local and regional technological plateforms
• Clinical Research Infrastructures

19
Main Inserms priorities

1.  Researchers  Careers, Training Mobility
2. To focus Inserm on its main mission support both
   basic and clinical research develop
   translational research with a multidisciplinary
   approach
3. To establish Inserm in a European and
   International context
4. To develop public/private partnerships

20
Career tracks at Inserm

• Junior, temporary contract (5 years with a 3-year
  intermediate evaluation), high level (research
  director) contracts
• Avenir program
• European programs EURYI, ERC

• Permanent positions for senior scientists

21
AVENIR Programme

• Eligibility Young scientists with permanent or
  temporary position, clinicians
• Aim To strengthen the status of young
  scientists to recognize, evaluate and
  continuously promote scientific qualities
• Each successful candidate is allocated
• A yearly budget of 60 K euros
• Minimum lab space of 50 m2
• Personnel 1 post-graduate collaborator and 1
  graduate student
• Each successful young scientist receives a salary
  for 5 years

22
ERC - European Research CouncilThe 7th FP - EU

• Attractive research environment at Inserm
• 335 Research units incl. 19 Research centers
• Performing research infrastructures incl. 41
  Clinical Reserach Centers
• Public-Private partnerships - Innovation
• Salary up to 7k monthly
• Potential tenure career track

• Programme dedicated to Frontier research
• Targeted to
• Young researchers
• Starting Independent Research Grant
• Advanced researchers
• Advanced Investigator Research Grant
• 100 to 400 K/year up to 5 years

23
Interface contracts General principles

• Based on
• a permanent position temporary, 3-5 year
  contracts
• To reinforce interactions with partners and
  mobility
• Hospitals clinical research, medical issues
• Health agencies health policy issues
• Universities teaching, making scientific
  information available to the society
• Industry technological transfer and
  valorisation
• European partners / European mobility (a new
  scheme of the Marie Curie actions - PEOPLE
  programme ?)

24
Interface contracts for Inserm scientists
Tenure position 3-5 year contracts " 2/3
1/3 "
25
Interface  Contract grants for MDs

• Reinforce research activities of clinicians and
  university research assistants and professors

• 3-5 year contracts for clinicians assistant
  professors and
• professors, university employees

• Grant paid by Inserm to hospitals and
  universities to be used for
• - clinical and teaching activities temporary
  positions
• - financing research activities

26
Interface contracts for MDs
HOSPITAL
INSERM
UNIVERSITY
INSERM
27
Joint post-doctoral career track Inserm-NIH

• 3-year post-doctoral positions in NIH Join
  selection by Inserm and NIH

• Evaluation at the end of post-doctoral
  fellowship

• Junior, 5-year Inserm contract

• Tenure Inserm, CNRS, University, industry etc ..

28
The School of Inserm
A 3-year Theoretical and Practical Education
which leads to a Masters

• First year of Inserm School - Second year of
  Medical School
• Special School Intensive Training Session in
  February
• June Competitive Exam

• Second year of Inserm School - Third year of
  Medical School
• 6 month full time Research Clerkship in an Inserm
  Research Laboratory

• Third year of Inserm School - Interruption of
  Medical School Clerkship in a Research
  Laboratory and educational program for the Master
  Degree

29
Clinical research and Translational research
strategy
30
Clinical trials
Inserm
Inserm
Inserm
Proof of concept Phases I-IIa Biotherapy
Preclinical studies  Proof of concept
Basic Research
Phase IV Cohorts
Phases IIb-III
CRC
31
Clinical research infrastructures
2006 2001 2002 2003 2004 2005
Clinical research centers 41 17 21 28 31 41
Tissues Banks 47 16 30 47 47 47
Cohorts 118 131 135 142 147 147
Registries 35 17 29 29 31 35
Networks 22 9 22 22 22 22
32
Finland FinnCRIN
European Clinical Research Infrastructures
Network, co-ordinated by INSERM Pan-European infr
astructure providing services to the preparation
and the conduct of multinational clinical
studies, with GMP facilities for biotherapy
Sweden SweCRIN
Denmark DCRIN
Ireland ICRIN
UK UKCRN
EORTC
Germany KKS
EFGCP
Austria ATCRIN
France Inserm
Hungary HECRIN
Switzerland SCRN
Spain SCReN
Italy IRFMN CIRM
National networks of Clinical Research Centres /
Clinical Trial Units
33
Network of Biological Resources Facilities
Cohorts of Patients

• Science Case
• A European network to coordinate European
  Scientific programs and policies
• Clinical data and follow-up of patients and
  Healthy volunteers
• Innovative targets, biomarkers, clinical studies
• Technology transfer, dissemination of knowledge,
  valorisation
• Technical case
• Repositories for qualified biological samples
  (DNA, RNA, proteins,), coupled to clinical data.
• Providers/distributors of samples within
  scientific project objectives
• Development of QA standards for European BRCs
• To store samples for the future (heritage)
• Distributed facilities / centralised database

34
EU approach for of GMP Facilities

• Needs to develop innovative non-commercial
  clinical trials - Lack of specific financial
  support
• Science Case
• Reinforcing clinical research and translation of
  basic research to therapy
• Production and evaluation of innovative
  therapeutic and diagnostic agents biomarkers
  and biotherapy / regenerative medicine cell
  therapy, gene therapy, tissue engineering
• Technical case
• Production of new therapeutic/diagnostic agents
  from biotechnologies
• Products for Cell and Gene therapy
• Good Manufacturing Practices (GMO dissemination
  regulation), in line with national legislation,
  able to cooperate across the borders
• Direct links with Clinical Research Centres (CRC
  - ECRIN)

35
IMI Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to
develop new therapeutic drugs in a faster and
safer way. Inserm is the French representative
in the Member states contact Group of IMI
36
Regional clusters

1. Canceropoles, other thematic poles (Neuropole, )
   
2. Competitivity clusters (Industry)
3. Regional poles for research in Neurosciences, etc.

37
Competitivity Clusters
67 created clusters 7 involving Inserm units
38
The European policy of Inserm
39
The main axes

• EU Prospectives (ESF-EMRC, EUROHORCS,etc.)
• Participation in European programmes RTD FP
  Public Health FP
• Infrastructures - ESFRI (ECRIN, )
• Researchers mobility within EU programmes and
  
• Bilateral actions Common Research projects
  - Associated laboratories - Joint-units abroad

40
Multilateral cooperations actions
Participation to the European Research and
Public Health programmes
Inserm and The 6th Framework Programme of the EU

• around 166 EU research projects
• 26 in coordination
• (success rate 50 last FP6 calls)
• (preliminary data - April 2007)

Inserm and The 7th Framework Programme of the
EU (2007 - 2013)
41

• European Mobility of Researchers
•  Towards a European Career Track 

• International Cooperation Contracts (up to 4
  years)
• Salary paid by home institution additional
  salary paid by host institution
• Reciprocal, bi-directional
• gt Marie Curie  Co-fund  Programme (FP7)
• Joint Post-doctoral training contracts
• 2 phases, commitment for a contractual
  recruitment when they return, bidirectional call
  for application
• Prospectives towards Internationalisation of
  School of Inserm

42
Joint post-doctoral career track

• 3-year post-doctoral positions in host
  institutions Joint selection with Inserm
• Joint calls under preparation with European
  institutions (ICL, Univ. Dundee, Porto)

• Evaluation at the end of post-doctoral
  fellowship

• Junior, 5-year Inserm contract

• Tenure Inserm, CNRS, University, industry etc ..

43
Cooperations between Inserm and Czech Partners (1)

• 20 cooperation projects undertaken since 2000gt
  more than 100 common publications (38 in 2006)
• Main cities Prague, Olomuc, Brno
• Main Partner Institutions Academy of Sciences
  of the Czech Republic, Charles University Prague,
  etc.
• Main thematic areas Neurosciences,
  Microbiology, Nutrition, Molecular Biology,
  Toxicology etc.
• 3 Czech Post-docs, Researchers and Fellows within
  Inserm's research units in 2006

43
44
Cooperations between Inserm and Czech Partners (2)

• European Associated Laboratory (EAL)
• Clinical Research on Obesity
• D. Langin, Toulouse V. Stich, Charles
  University Prague
• In the frame of the 6th EU Framework programme
• 23 European research projects mainly in the LSH
  priority
• (7 NoEs - 12 IPs - 4 STREP) - 3 of them involved
  the EAL
• Future collaborations within the FP7
• Health priority, IMI, Infrastructures (ECRIN,
  BRCs)

44
45
Bilateral cooperations tools Associated
Laboratories and Inserms Units abroad

• Scientifically driven
• 8 years mandate with mid-term evaluation
• Synergies competencies and facility access
• Co-funded by Inserm and Associated partner
• Temporary/permanent positions (Mobility of
  Post-Doc, researchers - Interface contracts)
• Institutional label
• Leverage effect for additional funding

46

• European Associated Laboratories (LEA)
• Toulouse D. Langin U586 / Prague V. Stich
  (Univ. Charles)
• Lille M. Capron U547 / Brussels M. Goldman
  (IMI)
• Toulouse AC Prats U589 / Dundee JC Bourdon
  (Univ. Dundee)
• Bordeaux A. Bikfalvi E 113 / Milan L. Bello
  (Univ. Degli Stuli)
• Nice G. Meneguzzi U 634 / Rome G. Zambruno
  (IDI-IRCCS)
• Villejuif D. Samuel U 785 / Rome M. Levrero
  (Univ. La Sapienza)
• Montpellier K. Ritchie U 888 / London G.
  Thornicroft (Kings College of London)
• Strasbourg T. Baumert U 748 / Freiburg H. Blum
  (Univ. of Freiburg)
• Villejuif T. Moreau U 780/ Barcelona J. Ant?
  (PRBB, IMIM-CREAL)
• Bordeaux L. Bordenave U 577 / Porto M. Barbosa
  (IBMC, INEB)

Glasgow
Dundee

• Joint Research Unit in Europe
• Université de Glasgow / C. Doerig U609
• DKFZ / J. Rommelaere U701

London
Heidelberg
Brussels
Prague
Freiburg
Milan
Barcelona
Porto
Rome
47
Montreal
Laval
Montréal
Seoul
Los Angeles
Beijing
Tokyo
New York
Haïfa
Wuhan
Rabat
Pittsburgh
Irvine
Kyoto
Nanjing
Shanghai
Dallas
Doha
Guangzhou
Singapour
Rio de Janeiro
INSERM Unit Associated Laboratory In preparation
Buenos Aires
48
Inserm Transfert

• Inserms private subsidiary
• Created in 2001, funded up to 4,5 million
• 60 people with scientific/industrial background
• Missions
• Drive value creation from Inserm research
• Allow an efficient partnering with the Industry
• Ensure a fair economic return towards Inserm
• Contribute to economic development

49
Integrated Technology Transfer SkillsFrom the
bench to the partnering and the license

• Development of services covering the whole
  technology transfer process
• Detection of inventions / coaching
• Protection of inventions follow up /
  intellectual property management
• Pre-technology transfer / Applied and
  Translational Research
• Technology Transfer, collaborative and RD
  agreements
• Preclinical Development / Proof of Concept
  development
• Industrial Partnerships / Clinical trials
  development
• International and European projects management
• Biotech start up coaching and funding (pre seed
  fund Inserm Transfert Initiative)
• Legal and financial expertise
• Proximity between both scientific and industrial
  communities
• for a best partnership development

50
Inserm Transfert Bridging the gap between
Science and Business
PARTNERS
INSERM
International Projects
L e g a l
F i n a n c e
Grants Consortium
A D R
R E S E A R C H
NewCo Creation Seed Fund
Spin-Off
T E A M S
Business Devpt

• Industrial
• Partnership
• Collaboration
• Licence

Intellectual Property
INNOVATION
KNOW HOW
51
Key figures

• 615 Patent families
• 373 Companies interacting with Inserm
• 481 License agreements
• 546 Technology transfer contracts

• 5,2 million/year of licensing income
• 15,4 million/year of RD contracts

• 31 european and international projects under
  management
• Total budget over 200 million
• 11 biotech start-up created since 2001 that have
  raised above 85 million euros near venture
  capitalists and financial partners

52
Contacts Inserms web site www.inserm.fr/en/in
serm

• Department of French Regional and European
  Strategic Policies
• Anne Bisagni, Director anne.bisagni_at_tolbiac.ins
  erm.fr
• Philippe Arhets, Deputy Director
  philippe.arhets_at_tolbiac.inserm.fr
• Cécile Bergouignan, Bilateral cooperation
  cecile.bergouignan_at_tolbiac.inserm.fr
• Human Resources Researchers task force
• Anne-Marie Laffaye, School of Inserm, Avenir
  anne-marie.laffaye_at_tolbiac.inserm.fr
• Richard Salives, Marie Curie Programme
  richard.salives_at_tolbiac.inserm.fr